Remogliflozin Tablet
Description
REMOROOT-1000
Remogliflozin Etabonate 1000 mg Tablets
Division: DIABGLYM
Composition
Each film-coated tablet contains:
Remogliflozin Etabonate IP — 1000 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Film-coated oral tablet
Product Description
REMOROOT-1000 contains Remogliflozin Etabonate 1000 mg, a selective Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor formulated for the effective management of Type 2 Diabetes Mellitus. Remogliflozin lowers blood glucose levels by reducing renal glucose reabsorption and increasing urinary glucose excretion, thereby improving glycemic control through an insulin-independent mechanism.
Remogliflozin is widely used in diabetology and metabolic medicine for patients with Type 2 diabetes, particularly those with inadequate glycemic control, obesity, insulin resistance, metabolic syndrome, and cardiovascular risk factors. It provides effective reduction of fasting and postprandial blood glucose levels while supporting weight reduction and improved metabolic health.
REMOROOT-1000 is particularly beneficial for patients with Type 2 diabetes requiring additional glycemic control, overweight or obese diabetic patients, individuals with hypertension and metabolic syndrome, and those requiring combination therapy with other oral antidiabetic agents.
Technical Knowledge of Remogliflozin Etabonate
Remogliflozin Etabonate is a prodrug that is converted to the active compound Remogliflozin after oral administration. It selectively inhibits SGLT2 transporters located in the proximal renal tubules, reducing glucose reabsorption from the glomerular filtrate and increasing urinary glucose excretion.
This insulin-independent mechanism lowers plasma glucose levels, reduces glucotoxicity, improves glycemic control, and contributes to modest weight reduction and blood pressure lowering. The reduction in renal glucose reabsorption also helps decrease the renal threshold for glucose excretion.
Mechanism of Action
Remogliflozin selectively inhibits SGLT2 transporters, reduces renal glucose reabsorption, increases urinary glucose excretion, lowers fasting and postprandial blood glucose levels, improves glycemic control, and supports weight and metabolic management.
Key Benefits
Effective reduction of blood glucose levels
Insulin-independent glucose lowering
Improves HbA1c control
Reduces fasting and postprandial glucose
Supports weight reduction
May help improve blood pressure control
Can be used in combination with other antidiabetic therapies
Suitable for long-term diabetes management under medical supervision
Clinical Applications
REMOROOT-1000 is commonly prescribed for Type 2 Diabetes Mellitus, inadequate glycemic control with diet and exercise, combination therapy with metformin, combination therapy with DPP-4 inhibitors, obesity-associated diabetes, metabolic syndrome, and patients requiring additional glycemic control with an SGLT2 inhibitor.
Facts About Remogliflozin Etabonate
Remogliflozin is a selective SGLT2 inhibitor that lowers blood glucose independently of insulin secretion, making it effective across different stages of Type 2 diabetes. Increased urinary glucose excretion contributes to improved glycemic control, modest weight loss, and reduction of glucotoxicity. SGLT2 inhibitors have become an important component of modern diabetes management due to their metabolic and cardiovascular benefits.
Key Facts
Selective SGLT2 inhibitor
Remogliflozin Etabonate 1000 mg for effective glycemic control
Insulin-independent mechanism of action
Supports weight and metabolic management
Suitable for combination antidiabetic therapy
Evidence-based modern diabetes therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
REMOROOT-1000 is an excellent product for PCD Pharma Franchise, Diabetology Franchise, and Cardio-Diabetic Franchise across India. The rapidly increasing prevalence of Type 2 diabetes, obesity, metabolic syndrome, and lifestyle-related metabolic disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose REMOROOT-1000 for PCD Pharma Franchise?
High prescription potential
Strong physician and diabetologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Remogliflozin Etabonate 1000 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
REMOROOT-1000 from DIABGLYM combines effective glucose lowering, modern SGLT2 inhibitor therapy, comprehensive metabolic support, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, diabetologists, endocrinologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Remogliflozin formulation.
